NCT06263010 (Allo-PD) is a Phase 1 clinical trial of Allopregnanolone in Parkinson Disease, sponsored by Roberta Brinton.

Who is sponsoring NCT06263010?

NCT06263010 is sponsored by Roberta Brinton.

What drugs are being tested in NCT06263010?

Interventions in NCT06263010: Allopregnanolone.

What condition does NCT06263010 study?

NCT06263010 studies Parkinson Disease.

Is NCT06263010 still recruiting?

NCT06263010 is currently completed. Last updated 13 March 2026.

Last reviewed 2026-03-13 · How we verify

NCT06263010: Allo-PD

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Allopregnanolone as a Regenerative Treatment for Parkinson's Disease

Completed Phase 1 Last updated 13 March 2026

What this trial tests

Phase 1 trial testing Allopregnanolone in Parkinson Disease in 10 participants. Completed in 15 July 2025.

Timeline

12 January 2024

Primary endpoint
15 July 2025

15 July 2025

Quick facts

Lead sponsor	Roberta Brinton
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	non randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	10
Start date	12 January 2024
Primary completion	15 July 2025
Estimated completion	15 July 2025
Sites	1 location across United States

Drugs / interventions tested

Allopregnanolone — full drug profile →

Conditions studied

Parkinson Disease — all drugs for Parkinson Disease →

Sponsor

Roberta Brinton

Who can join

Adults 40 to 85, any sex, with Parkinson Disease. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The goal of this open-label, pilot clinical trial is to test allopregnanolone as a regenerative treatment in patients with Parkinson's disease (PD). The main questions this study aims to answer are: 1. Is a large-scale clinical trial testing how well it works in patients with PD feasible? 2. Is allopregnanolone safe and well-tolerated in patients with PD. 3. Can we see any signals of changes in imaging and clinical scales? Participants will receive a weekly infusion in their vein of allopregnanolone for a total of 12 weeks. There is no placebo so everyone receives allopregnanolone and "Open-label" means the study is not blinded so both the participant and investigators know the assigned treatment.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Should old acquaintance be forgot: A call for recognition and inclusion of advanced Parkinson's disease patients & care partners in evolving research models.
Park JS, Pensyl C, Manak TJ, Fleisher JE. · · 2025 · PMID 40645862 · DOI 10.1016/j.parkreldis.2025.107949

Verify or expand the search:

Other trials of Allopregnanolone

Trials testing the same drug.

NCT04003285 — Allopregnanolone in Chronic Complex Traumatic Brain Injury · Phase 2 · not yet recruiting
NCT04838301 — Allopregnanolone Regenerative Therapeutic for Mild Alzheimer's Disease · Phase 2 · recruiting
NCT03748303 — Allopregnanolone Regenerative Therapeutic for Early Alzheimer's Disease: Intramuscular Study · Phase 1 · terminated
NCT04015869 — Effect of Allopregnanolone on Stress-induced Craving · Phase 1 · completed

Other recruiting trials for Parkinson Disease

Currently open trials in the same condition.

NCT07399496 — Accelerated TMS for Apathy in PD · NA · recruiting
NCT07371338 — Phase 1 Clinical Trial to Evaluate the Safety, Efficacy, and Pharmacokinetics of IPS101A in Parkinson's Disease Patients · Phase 1 · recruiting
NCT07442370 — The Effect of Functional Rotational Exercises on Fall Risk and Mobility in Parkinson's Disease Patients · NA · recruiting
NCT06848205 — Percept Transitions in FOG and PD · NA · recruiting
NCT07432958 — A Study to Evaluate the Effectiveness of Two Doses of AP-472 as Adjunctive Therapy to Levodopa in Parkinson's Disease (P · Phase 2 · recruiting

Other Roberta Brinton trials

Trials by the same sponsor.

NCT05664477 — PhytoSERM to Prevent Menopause Associated Decline in Brain Metabolism and Cognition · Phase 2 · active not recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06263010 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Roberta Brinton
Last refreshed: 13 March 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06263010.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing